NBTXR3 is Nanobiotix’s treatment in the works for solid tumors. Specifically, the company is focusing on locally advanced head and neck squamous cell carcinoma. The company says it has entered into final contract negotiations with a major global pharmaceutical company seeking rights to the drug.
According to Nanobiotix, the contract includes the development and commercialization of NBTXR3. Nanobiotix says that it won’t make any more comments on these negotiations until a deal is reached or they need to for another purpose.
What This Means for NBTX Stock
Nanobiotix closing in on a deal for NBTXR3 is a win for NBTX stock. If the company licenses it to a major company, it could result in sales around the world. That could lead to additional revenue and potential royalty payments.
With this news, shares of NBTX stock are seeing incredibly heavy trading on Friday. This has more than 2.5 million shares of the stock changing hands as of this writing. Investors will keep in mind that the daily average trading volume for the company’s shares is only about 2,000 units.
NBTX stock is up 106.5% as of Friday morning.
Investors looking for more of the most recent stock market news will want to stick around!
We’ve got all of the hottest stock market news traders need to know about for Friday! That includes the biggest pre-market stock movers this morning, the latest news affecting Mullen Automotive (NASDAQ:MULN) stock, and more.
More Friday Stock Market News
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
- MULN Stock Alert: The MULN Army Is Betting on the Next Meme Stock
- Don’t Expect MULN Stock to Stay Above $1
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.